{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:49:32Z","timestamp":1788238172020,"version":"build-2803163510"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"China National Major Project for New Drug Innovation","award":["2017ZX09304015"],"award-info":[{"award-number":["2017ZX09304015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00262-022-03224-2","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T14:02:45Z","timestamp":1654092165000},"page":"3071-3085","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"71","author":[{"given":"Haizhu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-4964","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"3224_CR1","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol Off J Am Soc Clin Oncol 22:2865\u20132872. https:\/\/doi.org\/10.1200\/JCO.2004.12.149","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3224_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/s1556-0864(15)31569-0","volume":"1","author":"AA Shi","year":"2006","unstructured":"Shi AA, Digumarthy SR, Temel JS, Halpern EF, Kuester LB, Aquino SL (2006) Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 1:205\u2013210. https:\/\/doi.org\/10.1016\/s1556-0864(15)31569-0","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"3224_CR3","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.1988.6.9.1474","volume":"6","author":"JB Sorensen","year":"1988","unstructured":"Sorensen JB, Hansen HH, Hansen M, Dombernowsky P (1988) Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol Off J Am Soc Clin Oncol 6:1474\u20131480. https:\/\/doi.org\/10.1200\/JCO.1988.6.9.1474","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3224_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/s0169-5002(98)00020-8","volume":"20","author":"K Kelly","year":"1998","unstructured":"Kelly K, Bunn PA Jr (1998) Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer 20:85\u201391. https:\/\/doi.org\/10.1016\/s0169-5002(98)00020-8","journal-title":"Lung Cancer"},{"key":"3224_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829\u2013838. https:\/\/doi.org\/10.1056\/NEJMoa1704795","journal-title":"N Engl J Med"},{"key":"3224_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.3118","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC et al (2018) CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2018.78.3118","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3224_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.lungcan.2019.05.029","volume":"134","author":"U Dafni","year":"2019","unstructured":"Dafni U, Tsourti Z, Vervita K, Peters S (2019) Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer 134:127\u2013140. https:\/\/doi.org\/10.1016\/j.lungcan.2019.05.029","journal-title":"Lung Cancer"},{"key":"3224_CR8","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S1470-2045(17)30693-9","volume":"19","author":"DR Camidge","year":"2018","unstructured":"Camidge DR, Lee EQ, Lin NU et al (2018) Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the response assessment in neuro-oncology brain metastases working group. Lancet Oncol 19:e20\u2013e32. https:\/\/doi.org\/10.1016\/S1470-2045(17)30693-9","journal-title":"Lancet Oncol"},{"key":"3224_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2018.12.025","volume":"129","author":"L Crino","year":"2019","unstructured":"Crino L, Bronte G, Bidoli P et al (2019) Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 129:35\u201340. https:\/\/doi.org\/10.1016\/j.lungcan.2018.12.025","journal-title":"Lung Cancer"},{"key":"3224_CR10","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/j.cllc.2018.01.001","volume":"19","author":"K Kobayashi","year":"2018","unstructured":"Kobayashi K, Nakachi I, Naoki K et al (2018) Real-world efficacy and safety of nivolumab for advanced non-small-cell lung cancer: a retrospective multicenter analysis. Clin Lung Cancer 19:e349\u2013e358. https:\/\/doi.org\/10.1016\/j.cllc.2018.01.001","journal-title":"Clin Lung Cancer"},{"key":"3224_CR11","doi-asserted-by":"publisher","first-page":"e20601","DOI":"10.1200\/JCO.2017.35.15_suppl.e20601","volume":"35","author":"H Watanabe","year":"2017","unstructured":"Watanabe H, Kubo T, Ninomiya T, Ohashi K, Ichihara E, Sato A, Hotta K, Tabata M, Kiura K (2017) The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer. J Clin Oncol 35:e20601\u2013e20601. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.e20601","journal-title":"J Clin Oncol"},{"key":"3224_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.lungcan.2017.12.008","volume":"116","author":"C Gauvain","year":"2018","unstructured":"Gauvain C, Vaul\u00e9on E, Chouaid C, Le Rhun E, Jabot L, Scherpereel A, Vinas F, Cortot AB, Monnet I (2018) Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung Cancer 116:62\u201366. https:\/\/doi.org\/10.1016\/j.lungcan.2017.12.008","journal-title":"Lung Cancer"},{"key":"3224_CR13","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","volume":"14","author":"LEL Hendriks","year":"2019","unstructured":"Hendriks LEL, Henon C, Auclin E et al (2019) Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 14:1244\u20131254. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.009","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"3224_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123707","author":"M Skribek","year":"2020","unstructured":"Skribek M, Rounis K, Makrakis D, Agelaki S, Mavroudis D, De Petris L, Ekman S, Tsakonas G (2020) Outcome of patients with NSCLC and brain metastases treated with immune checkpoint inhibitors in a \u2018real-life\u2019 setting. Cancers. https:\/\/doi.org\/10.3390\/cancers12123707","journal-title":"Cancers"},{"key":"3224_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00262-019-02462-1","volume":"69","author":"G Zhang","year":"2020","unstructured":"Zhang G, Cheng R, Wang H et al (2020) Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study. Cancer Immunol Immunother CII 69:399\u2013405. https:\/\/doi.org\/10.1007\/s00262-019-02462-1","journal-title":"Cancer Immunol Immunother CII"},{"key":"3224_CR16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/s1470-2045(20)30111-x","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg SB, Schalper KA, Gettinger SN et al (2020) Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol 21:655\u2013663. https:\/\/doi.org\/10.1016\/s1470-2045(20)30111-x","journal-title":"Lancet Oncol"},{"key":"3224_CR17","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https:\/\/doi.org\/10.1136\/bmj.b2535","journal-title":"BMJ"},{"key":"3224_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"3224_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"3224_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"3224_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"3224_CR22","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088\u20131101","journal-title":"Biometrics"},{"key":"3224_CR23","doi-asserted-by":"publisher","first-page":"e0195945","DOI":"10.1371\/journal.pone.0195945","volume":"13","author":"C Dumenil","year":"2018","unstructured":"Dumenil C, Massiani MA, Dumoulin J, Giraud V, Labrune S, Chinet T, Giroux Leprieur E (2018) Clinical factors associated with early progression and grade 3\u20134 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. PLoS ONE 13:e0195945. https:\/\/doi.org\/10.1371\/journal.pone.0195945","journal-title":"PLoS ONE"},{"key":"3224_CR24","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N et al (2018) Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients With non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 36:2872\u20132878. https:\/\/doi.org\/10.1200\/JCO.2018.79.0006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3224_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.lungcan.2017.11.015","volume":"126","author":"E Dudnik","year":"2018","unstructured":"Dudnik E, Moskovitz M, Daher S et al (2018) Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data. Lung Cancer 126:217\u2013223. https:\/\/doi.org\/10.1016\/j.lungcan.2017.11.015","journal-title":"Lung Cancer"},{"key":"3224_CR26","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1007\/s12094-017-1829-5","volume":"20","author":"J Garde-Noguera","year":"2018","unstructured":"Garde-Noguera J, Martin-Martorell P, De Juli\u00e1n M et al (2018) Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients. Clin Transl Oncol Off Publ Fed Span Oncol Soc Nat Cancer Inst Mex 20:1072\u20131079. https:\/\/doi.org\/10.1007\/s12094-017-1829-5","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Nat Cancer Inst Mex"},{"key":"3224_CR27","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3747\/co.25.4287","volume":"25","author":"RA Juergens","year":"2018","unstructured":"Juergens RA, Mariano C, Jolivet J et al (2018) Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort. Curr Oncol 25:384\u2013392. https:\/\/doi.org\/10.3747\/co.25.4287","journal-title":"Curr Oncol"},{"key":"3224_CR28","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1002\/cam4.1825","volume":"7","author":"P Lesueur","year":"2018","unstructured":"Lesueur P, Escande A, Thariat J et al (2018) Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: a multicentric retrospective study from the GFPC. Cancer Med 7:5505\u20135513. https:\/\/doi.org\/10.1002\/cam4.1825","journal-title":"Cancer Med"},{"key":"3224_CR29","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","volume":"13","author":"SC Scott","year":"2018","unstructured":"Scott SC, Pennell NA (2018) Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 13:1771\u20131775. https:\/\/doi.org\/10.1016\/j.jtho.2018.06.004","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"3224_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192227","author":"M Tamiya","year":"2018","unstructured":"Tamiya M, Tamiya A, Inoue T et al (2018) Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial. PLoS ONE 13. https:\/\/doi.org\/10.1371\/journal.pone.0192227","journal-title":"PLoS ONE"},{"key":"3224_CR31","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/0284186x.2019.1615636","volume":"58","author":"B Bj\u00f8rnhart","year":"2019","unstructured":"Bj\u00f8rnhart B, Hansen KH, J\u00f8rgensen TL, Herrstedt J, Schytte T (2019) Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncol 58:953\u2013961. https:\/\/doi.org\/10.1080\/0284186x.2019.1615636","journal-title":"Acta Oncol"},{"key":"3224_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.09.011","volume":"123","author":"F Grossi","year":"2019","unstructured":"Grossi F, Genova C, Crino L et al (2019) Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. Eur J Cancer 123:72\u201380. https:\/\/doi.org\/10.1016\/j.ejca.2019.09.011","journal-title":"Eur J Cancer"},{"key":"3224_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2019.05.033","volume":"134","author":"D Lang","year":"2019","unstructured":"Lang D, Horner A, Brehm E et al (2019) Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1\/PD-L1 inhibitor treated advanced NSCLC\u2014a retrospective cohort study. Lung Cancer 134:59\u201365. https:\/\/doi.org\/10.1016\/j.lungcan.2019.05.033","journal-title":"Lung Cancer"},{"key":"3224_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001007","author":"JV Alessi","year":"2020","unstructured":"Alessi JV, Ricciuti B, Jim\u00e9nez-Aguilar E et al (2020) Outcomes to first-line pembrolizumab in patients with PD-L1-high (\u2265\u00a050%) non-small cell lung cancer and a poor performance status. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-001007","journal-title":"J Immunother Cancer"},{"key":"3224_CR35","doi-asserted-by":"publisher","first-page":"1744898","DOI":"10.1080\/2162402x.2020.1744898","volume":"9","author":"F Barlesi","year":"2020","unstructured":"Barlesi F, Dixmier A, Debieuvre D et al (2020) Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. Oncoimmunology 9:1744898. https:\/\/doi.org\/10.1080\/2162402x.2020.1744898","journal-title":"Oncoimmunology"},{"key":"3224_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/cji.0000000000000340","volume":"43","author":"G Metro","year":"2020","unstructured":"Metro G, Banna GL, Signorelli D et al (2020) Efficacy of pembrolizumab monotherapy in patients with or without brain metastases from advanced non-small cell lung cancer With a PD-L1 expression \u2265\u00a050%. J Immunother 43:299\u2013306. https:\/\/doi.org\/10.1097\/cji.0000000000000340","journal-title":"J Immunother"},{"key":"3224_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.lungcan.2019.12.011","volume":"140","author":"HJM Smit","year":"2020","unstructured":"Smit HJM, Aerts J, van den Heuvel M et al (2020) Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry. Lung Cancer 140:107\u2013112. https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.011","journal-title":"Lung Cancer"},{"key":"3224_CR38","doi-asserted-by":"publisher","first-page":"12777","DOI":"10.2147\/ott.S286600","volume":"13","author":"C Sun","year":"2020","unstructured":"Sun C, Zhou F, Li X et al (2020) PD-1\/PD-L1 inhibitor combined with chemotherapy can improve the survival of non-small cell lung cancer patients with brain metastases. Onco Targets Ther 13:12777\u201312786. https:\/\/doi.org\/10.2147\/ott.S286600","journal-title":"Onco Targets Ther"},{"key":"3224_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.02.001","author":"N Frost","year":"2021","unstructured":"Frost N, Kollmeier J, Misch D et al (2021) Pembrolizumab as first-line palliative therapy in PD-L1 overexpressing (\u2265\u00a050%) NSCLC: real-world results with special focus on PS \u2265\u00a02, brain metastases, and steroids. Clin Lung Cancer. https:\/\/doi.org\/10.1016\/j.cllc.2021.02.001","journal-title":"Clin Lung Cancer"},{"key":"3224_CR40","doi-asserted-by":"publisher","first-page":"1909296","DOI":"10.1080\/2162402x.2021.1909296","volume":"10","author":"SC Ma","year":"2021","unstructured":"Ma SC, Tang XR, Long LL et al (2021) Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. Oncoimmunology 10:1909296. https:\/\/doi.org\/10.1080\/2162402x.2021.1909296","journal-title":"Oncoimmunology"},{"key":"3224_CR41","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/j.cllc.2020.09.017","volume":"22","author":"G Mountzios","year":"2021","unstructured":"Mountzios G, de Toma A, Economopoulou P et al (2021) Steroid use independently predicts for poor outcomes in patients with advanced NSCLC and high PD-L1 expression receiving first-line pembrolizumab monotherapy. Clin Lung Cancer 22:e180\u2013e192. https:\/\/doi.org\/10.1016\/j.cllc.2020.09.017","journal-title":"Clin Lung Cancer"},{"key":"3224_CR42","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-1471","author":"M Qiao","year":"2021","unstructured":"Qiao M, Zhou F, Hou L et al (2021) Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases. Ann Transl Med. https:\/\/doi.org\/10.21037\/atm-20-1471","journal-title":"Ann Transl Med"},{"key":"3224_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cllc.2020.10.017","volume":"22","author":"L Sun","year":"2021","unstructured":"Sun L, Davis CW, Hwang WT et al (2021) Outcomes in patients with non-small-cell lung cancer with brain metastases treated with pembrolizumab-based therapy. Clin Lung Cancer 22:58-66.e3. https:\/\/doi.org\/10.1016\/j.cllc.2020.10.017","journal-title":"Clin Lung Cancer"},{"key":"3224_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lungcan.2020.11.009","volume":"151","author":"K Wakuda","year":"2021","unstructured":"Wakuda K, Yabe M, Kodama H et al (2021) Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression. Lung Cancer 151:60\u201368. https:\/\/doi.org\/10.1016\/j.lungcan.2020.11.009","journal-title":"Lung Cancer"},{"key":"3224_CR45","doi-asserted-by":"publisher","first-page":"628124","DOI":"10.3389\/fonc.2021.628124","volume":"11","author":"P Wang","year":"2021","unstructured":"Wang P, Fang X, Yin T, Tian H, Yu J, Teng F (2021) Efficacy and safety of anti-PD-1 plus anlotinib in patients with advanced non\u2013small-cell lung cancer after previous systemic treatment failure\u2014a retrospective study. Front Oncol 11:628124. https:\/\/doi.org\/10.3389\/fonc.2021.628124","journal-title":"Front Oncol"},{"key":"3224_CR46","doi-asserted-by":"publisher","first-page":"S2420","DOI":"10.1016\/j.jtho.2017.11.073","volume":"12","author":"H Ashinuma","year":"2017","unstructured":"Ashinuma H, Shingyoji M, Iuchi T, Yoshida Y, Setoguchi T, Hasegawa Y, Sakaida T (2017) P2. 07\u2013014 immune checkpoint inhibitors for brain metastases of non-small-cell lung cancer. J Thorac Oncol 12:S2420","journal-title":"J Thorac Oncol"},{"key":"3224_CR47","doi-asserted-by":"publisher","first-page":"S2417","DOI":"10.1016\/j.jtho.2017.11.064","volume":"12","author":"C Henon","year":"2017","unstructured":"Henon C, Mezquita L, Auclin E et al (2017) P2. 07\u2013005 impact of baseline leptomeningeal and brain metastases on immunotherapy outcomes in advanced non-small cell lung cancer (NSCLC) patients. J Thorac Oncol 12:S2417","journal-title":"J Thorac Oncol"},{"key":"3224_CR48","doi-asserted-by":"publisher","first-page":"S384","DOI":"10.1016\/j.jtho.2018.08.383","volume":"13","author":"M Geier","year":"2018","unstructured":"Geier M, Descourt R, Corre R et al (2018) MA08. 10 real-life intracerebral efficacy of nivolumab in non-small cell lung cancer patients with brain metastases. J Thorac Oncol 13:S384\u2013S385","journal-title":"J Thorac Oncol"},{"key":"3224_CR49","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1200\/JCO.19.03022","volume":"38","author":"NH Hanna","year":"2020","unstructured":"Hanna NH, Schneider BJ, Temin S et al (2020) Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol Off J Am Soc Clin Oncol 38:1608\u20131632. https:\/\/doi.org\/10.1200\/JCO.19.03022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3224_CR50","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jtho.2021.04.014","volume":"16","author":"T Loiola","year":"2021","unstructured":"Loiola T, de Alencar V, Guedes Camandaroba MP, Pirolli R, Fogassa CAZ, Cordeiro de Lima VC (2021) Immunotherapy as single treatment for patients with NSCLC with brain metastases: a systematic review and meta-analysis\u2014the META-L-BRAIN study. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 16:1379\u20131391. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.014","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"3224_CR51","doi-asserted-by":"publisher","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","volume":"115","author":"D Taggart","year":"2018","unstructured":"Taggart D, Andreou T, Scott KJ et al (2018) Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking. Proc Natl Acad Sci 115:E1540\u2013E1549. https:\/\/doi.org\/10.1073\/pnas.1714089115","journal-title":"Proc Natl Acad Sci"},{"key":"3224_CR52","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/annonc\/mdw289","volume":"27","author":"AS Mansfield","year":"2016","unstructured":"Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H (2016) Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol Off J Eur Soc Med Oncol 27:1953\u20131958. https:\/\/doi.org\/10.1093\/annonc\/mdw289","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"3224_CR53","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/annonc\/mdz207","volume":"30","author":"Y Kudo","year":"2019","unstructured":"Kudo Y, Haymaker C, Zhang J et al (2019) Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol 30:1521\u20131530. https:\/\/doi.org\/10.1093\/annonc\/mdz207","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"3224_CR54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255\u2013265. https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X","journal-title":"Lancet"},{"key":"3224_CR55","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"3224_CR56","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"3224_CR57","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064\u20135074. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3271","journal-title":"Clin Cancer Res"},{"key":"3224_CR58","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17:e542\u2013e551. https:\/\/doi.org\/10.1016\/S1470-2045(16)30406-5","journal-title":"Lancet Oncol"},{"key":"3224_CR59","doi-asserted-by":"publisher","first-page":"102067","DOI":"10.1016\/j.ctrv.2020.102067","volume":"89","author":"N Vilarino","year":"2020","unstructured":"Vilarino N, Bruna J, Bosch-Barrera J, Valiente M, Nadal E (2020) Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Cancer Treat Rev 89:102067. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102067","journal-title":"Cancer Treat Rev"},{"key":"3224_CR60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.lungcan.2019.04.009","volume":"132","author":"H Wang","year":"2019","unstructured":"Wang H, Agulnik J, Kasymjanova G et al (2019) The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma. Lung Cancer 132:36\u201338. https:\/\/doi.org\/10.1016\/j.lungcan.2019.04.009","journal-title":"Lung Cancer"},{"key":"3224_CR61","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","volume":"23","author":"C Zhou","year":"2022","unstructured":"Zhou C, Wang Z, Sun Y et al (2022) Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol 23:220\u2013233. https:\/\/doi.org\/10.1016\/S1470-2045(21)00650-1","journal-title":"Lancet Oncol"},{"key":"3224_CR62","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou C, Chen G, Huang Y et al (2021) Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med 9:305\u2013314. https:\/\/doi.org\/10.1016\/S2213-2600(20)30365-9","journal-title":"Lancet Respir Med"},{"key":"3224_CR63","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","volume":"15","author":"Y Yang","year":"2020","unstructured":"Yang Y, Wang Z, Fang J et al (2020) Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 15:1636\u20131646. https:\/\/doi.org\/10.1016\/j.jtho.2020.07.014","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"3224_CR64","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","volume":"14","author":"YL Wu","year":"2019","unstructured":"Wu YL, Lu S, Cheng Y et al (2019) Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 14:867\u2013875. https:\/\/doi.org\/10.1016\/j.jtho.2019.01.006","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"3224_CR65","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"A Sezer","year":"2021","unstructured":"Sezer A, Kilickap S, Gumus M et al (2021) Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 397:592\u2013604. https:\/\/doi.org\/10.1016\/S0140-6736(21)00228-2","journal-title":"Lancet"},{"key":"3224_CR66","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol Off J Am Soc Clin Oncol 37:537\u2013546. https:\/\/doi.org\/10.1200\/JCO.18.00149","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3224_CR67","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"3224_CR68","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22:198\u2013211. https:\/\/doi.org\/10.1016\/S1470-2045(20)30641-0","journal-title":"Lancet Oncol"},{"key":"3224_CR69","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R et al (2019) Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381:2020\u20132031. https:\/\/doi.org\/10.1056\/NEJMoa1910231","journal-title":"N Engl J Med"},{"key":"3224_CR70","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","volume":"128","author":"SM Gadgeel","year":"2019","unstructured":"Gadgeel SM, Lukas RV, Goldschmidt J et al (2019) Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study. Lung Cancer 128:105\u2013112. https:\/\/doi.org\/10.1016\/j.lungcan.2018.12.017","journal-title":"Lung Cancer"},{"key":"3224_CR71","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodriguez-Abreu D, Speranza G et al (2020) Updated Analysis From KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 38:1505\u20131517. https:\/\/doi.org\/10.1200\/JCO.19.03136","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3224_CR72","doi-asserted-by":"publisher","first-page":"100205","DOI":"10.1016\/j.jtocrr.2021.100205","volume":"2","author":"AS Mansfield","year":"2021","unstructured":"Mansfield AS, Herbst RS, de Castro G Jr et al (2021) Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin Res Rep 2:100205. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100205","journal-title":"JTO Clin Res Rep"},{"key":"3224_CR73","doi-asserted-by":"publisher","first-page":"702924","DOI":"10.3389\/fonc.2021.702924","volume":"11","author":"S Li","year":"2021","unstructured":"Li S, Zhang H, Liu T, Chen J, Dang J (2021) The effect of asymptomatic and\/or treated brain metastases on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: a meta-analysis. Front Oncol 11:702924. https:\/\/doi.org\/10.3389\/fonc.2021.702924","journal-title":"Front Oncol"},{"key":"3224_CR74","doi-asserted-by":"publisher","first-page":"669398","DOI":"10.3389\/fimmu.2021.669398","volume":"12","author":"H Hu","year":"2021","unstructured":"Hu H, Xu ZY, Zhu Q, Liu X, Jiang SC, Zheng JH (2021) Brain metastases status and immunotherapy efficacy in advanced lung cancer: a systematic review and meta-analysis. Front Immunol 12:669398. https:\/\/doi.org\/10.3389\/fimmu.2021.669398","journal-title":"Front Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03224-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03224-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03224-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T22:08:24Z","timestamp":1666562904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03224-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3224"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03224-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"19 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}